Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEBRA: Pembrolizumab in Advanced Small Bowel Adenocarcinoma
NCT02949219Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in small bowel adenocarcinoma (SBA), sponsored by Academic and Community Cancer Research United. Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT02949219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949219.